624 related articles for article (PubMed ID: 22836070)
1. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.
Græsdal A; Bogsrud MP; Holven KB; Nenseter MS; Narverud I; Langslet G; Brekke M; Retterstøl K; Arnesen KE; Ose L
J Clin Lipidol; 2012; 6(4):331-9. PubMed ID: 22836070
[TBL] [Abstract][Full Text] [Related]
2. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
Vishwanath R; Hemphill LC
J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.
Reijman MD; Tromp TR; Hutten BA; Hovingh GK; Blom DJ; Catapano AL; Cuchel M; Dann EJ; Gallo A; Hudgins LC; Raal FJ; Ray KK; Sadiq F; Soran H; Groothoff JW; Wiegman A; Kusters DM; ;
Lancet Child Adolesc Health; 2024 Jul; 8(7):491-499. PubMed ID: 38759658
[TBL] [Abstract][Full Text] [Related]
4. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.
Yamamoto A; Harada-Shiba M; Endo M; Kusakabe N; Tanioka T; Kato H; Shoji T
Atherosclerosis; 2006 May; 186(1):126-31. PubMed ID: 16043185
[TBL] [Abstract][Full Text] [Related]
5. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
Geiss HC; Otto C; Parhofer KG
Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations.
Stein EA; Dann EJ; Wiegman A; Skovby F; Gaudet D; Sokal E; Charng MJ; Mohamed M; Luirink I; Raichlen JS; Sundén M; Carlsson SC; Raal FJ; Kastelein JJP
J Am Coll Cardiol; 2017 Aug; 70(9):1162-1170. PubMed ID: 28838366
[TBL] [Abstract][Full Text] [Related]
7. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group.
Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T
Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years.
Palcoux JB; Atassi-Dumont M; Lefevre P; Hequet O; Schlienger JL; Brignon P; Roussel B
Ther Apher Dial; 2008 Jun; 12(3):195-201. PubMed ID: 18503695
[TBL] [Abstract][Full Text] [Related]
9. The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease.
Vogt A; Parhofer KG
Expert Opin Pharmacother; 2013 Apr; 14(6):691-7. PubMed ID: 23477485
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia.
Hudgins LC; Kleinman B; Scheuer A; White S; Gordon BR
Am J Cardiol; 2008 Nov; 102(9):1199-204. PubMed ID: 18940291
[TBL] [Abstract][Full Text] [Related]
12. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A
Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169
[TBL] [Abstract][Full Text] [Related]
13. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
Elis A; Zhou R; Stein EA
Am J Cardiol; 2011 Jul; 108(2):223-6. PubMed ID: 21545982
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
Bruckert E; Kalmykova O; Bittar R; Carreau V; Béliard S; Saheb S; Rosenbaum D; Bonnefont-Rousselot D; Thomas D; Emery C; Khoshnood B; Carrié A
Atherosclerosis; 2017 Feb; 257():130-137. PubMed ID: 28131047
[TBL] [Abstract][Full Text] [Related]
15. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy.
Raal FJ; Pilcher GJ; Panz VR; van Deventer HE; Brice BC; Blom DJ; Marais AD
Circulation; 2011 Nov; 124(20):2202-7. PubMed ID: 21986285
[TBL] [Abstract][Full Text] [Related]
16. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia.
Thiery J; Seidel D
Transfus Sci; 1993 Jul; 14(3):249-59. PubMed ID: 10146336
[TBL] [Abstract][Full Text] [Related]
17. Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study.
Raal FJ; Sjouke B; Hovingh GK; Isaac BF
Atherosclerosis; 2016 May; 248():238-44. PubMed ID: 27017151
[TBL] [Abstract][Full Text] [Related]
18. Ezetimibe treatment of pediatric patients with hypercholesterolemia.
Clauss S; Wai KM; Kavey RE; Kuehl K
J Pediatr; 2009 Jun; 154(6):869-72. PubMed ID: 19230898
[TBL] [Abstract][Full Text] [Related]
19. Apheresis technologies for prevention and regression of atherosclerosis: clinical results.
Bambauer R; Schneidewind JM; Latza R
ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615
[TBL] [Abstract][Full Text] [Related]
20. A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study.
Stefanutti C; Pang J; Di Giacomo S; Wu X; Wang X; Morozzi C; Watts GF; Lin J
J Clin Lipidol; 2019; 13(4):608-617. PubMed ID: 31255589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
